Phase II Chemoprevention Trial with High Dose Fenretinide for Oral Pre-Malignant Lesions

BACKGROUND: In a previous phase II trial, we demonstrated that fenretinide 200 mg/day had limited activity in retinoid-refractory leukoplakia (34% response rate), possibly due to the lack of achievement of high serum levels which would be required to elicit retinoid-receptor independent apoptosis in...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: William, William N., Lee, J. Jack, Lippman, Scott M., Martin, Jack W., Tran, Hai T., Sabichi, Anita L., Kim, Edward S., Feng, Lei, Papadimitrakopoulou, Vassiliki A.
格式: Artigo
語言:Inglês
出版: 2009
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4161148/
https://ncbi.nlm.nih.gov/pubmed/19139014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-08-0100
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍